Comparative Pharmacology
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus SUMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTETRACYCLINE HYDROCHLORIDE versus SUMYCIN.
OXYTETRACYCLINE HYDROCHLORIDE vs SUMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
None Documented
None Documented
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic